MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
1.790
-0.030
-1.65%
After Hours: 1.790 0 -0.01% 19:45 11/13 EST
OPEN
1.830
PREV CLOSE
1.820
HIGH
1.830
LOW
1.720
VOLUME
1.89M
TURNOVER
--
52 WEEK HIGH
2.680
52 WEEK LOW
1.100
MARKET CAP
796.97M
P/E (TTM)
-11.9813
1D
5D
1M
3M
1Y
5Y
1D
Need To Know: Analysts Are Much More Bullish On Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Revenues
Simply Wall St · 2d ago
Piper Sandler Remains a Buy on Lexicon Pharmaceuticals (LXRX)
TipRanks · 4d ago
Lexicon Pharma Price Target Raised to $3.40/Share From $3.10 by Citigroup
Dow Jones · 5d ago
Lexicon Pharma Is Maintained at Buy by Citigroup
Dow Jones · 5d ago
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.4
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Geron (GERN) and Medacta Group SA (OtherMEDGF)
TipRanks · 5d ago
Lexicon Pharma Presents New Data Highlighting Cardiovascular Effects Of Dual SGLT1/2 Inhibitor, Sotagliflozin, At AHA Scientific Sessions 2026
Benzinga · 5d ago
Weekly Report: what happened at LXRX last week (1102-1106)?
Weekly Report · 5d ago
More
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.

Webull offers Lexicon Pharmaceuticals Inc stock information, including NASDAQ: LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.